{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:47:01Z","timestamp":1792118821681,"version":"4.4.0"},"reference-count":112,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The last decade has been very important for the quantity of preclinical information obtained regarding chronic myeloproliferative neoplasms (MPNs) and the following will be dedicated to the translational implications of the new biological acquisitions. The overcoming of the mechanistic model of clonal evolution and the entry of chronic inflammation and dysimmunity into the new model are the elements on which to base a part of future therapeutic strategies. The innate immune system plays a major role in this context. Protagonists of the initiation and regulation of many pathological aspects, from cytokine storms to fibrosis, the NLRP3 and AIM2 inflammasomes guide and condition the natural history of the disease. For this reason, MPNs share many biological and clinical aspects with non-neoplastic diseases, such as autoimmune disorders. Finally, cardiovascular risk and disturbances in iron metabolism and myelopoiesis are also closely linked to the role of inflammasomes. Although targeted therapies are already being tested, an increase in knowledge on the subject is desirable and potentially translates into better care for patients with MPNs.<\/jats:p>","DOI":"10.3390\/ijms22020561","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:55:56Z","timestamp":1610308556000},"page":"561","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-3643","authenticated-orcid":false,"given":"Valeria","family":"Di Battista","sequence":"first","affiliation":[{"name":"Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-9189","authenticated-orcid":false,"given":"Maria Teresa","family":"Bochicchio","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-5028","authenticated-orcid":false,"given":"Giulio","family":"Giordano","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Hematology Service, Regional Hospital \u201cA. Cardarelli\u201d, 86100 Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Haematology Unit, University Hospital \u201cP. Giaccone\u201d, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-5311","authenticated-orcid":false,"given":"Alessandro","family":"Lucchesi","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ajh.23678","article-title":"CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum","volume":"89","author":"Guglielmelli","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.7314\/APJCP.2016.17.3.923","article-title":"Coexisting JAK2V617F and CALR exon 9 mutations in myeloproliferative neoplasms\u2014Do they designate a new subtype?","volume":"17","author":"Ahmed","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3346\/jkms.2015.30.7.882","article-title":"JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis","volume":"30","author":"Kim","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1182\/blood.V128.22.3134.3134","article-title":"Endothelial JAK2V617F Expression Drives Inflammation and Cellular Senescence; New Evidence for the Roles of Endothelial Cells in MPN-Related Clotting Abnormalities?","volume":"128","author":"Cosgrove","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-014-0080-6","article-title":"Immunosuppressive\/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction-A novel mechanism for maintaining vascular function","volume":"7","author":"Shao","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00395-008-0733-0","article-title":"The role of inflammatory cytokines in endothelial dysfunction","volume":"103","author":"Zhang","year":"2008","journal-title":"Basic Res. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development","volume":"2015","author":"Geyer","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and myeloproliferative neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT Signaling Pathway: Input and Output Integration","volume":"178","author":"Murray","year":"2007","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s000180050394","article-title":"The role of STATs in proliferation, differentiation, and apoptosis","volume":"55","author":"Mui","year":"1999","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002770050595","article-title":"Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis","volume":"78","year":"1999","journal-title":"Ann. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1159\/000477253","article-title":"Clinical correlates and prognostic significance of IL-8, sIL-2R, and immunoglobulin-free light chain levels in patients with myelofibrosis","volume":"40","author":"Barabanshikova","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Vaddi","year":"2010","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F","volume":"30","author":"Boissinot","year":"2011","journal-title":"Oncogene"},{"key":"ref_34","first-page":"34","article-title":"A novel interaction between megakaryocytes and activated fibrocytes increases TGF-\u03b2 bioavailability in the Gata1(low) mouse model of myelofibrosis","volume":"5","author":"Zingariello","year":"2015","journal-title":"Am. J. Blood Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","article-title":"Characterization of the TGF-b1 signaling abnormalities in the Gata1low mouse model of myelofibrosis","volume":"121","author":"Zingariello","year":"2013","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Eran, Z., Zingariello, M., Bochicchio, M.T., Bardelli, C., and Migliaccio, A.R. (2019). Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology [version 1; peer review: 2 approved]. F1000Research.","DOI":"10.12688\/f1000research.18581.1"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1345402","DOI":"10.1080\/2162402X.2017.1345402","article-title":"Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis","volume":"6","author":"Romano","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.14507","article-title":"Detection of inflammatory monocytes but not mesenchymal stem\/stromal cells in peripheral blood of patients with myelofibrosis","volume":"181","author":"Correa","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1782575","DOI":"10.1080\/2162402X.2020.1782575","article-title":"The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis","volume":"9","author":"Barone","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.2019004095","article-title":"Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN","volume":"136","author":"Gleitz","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000360102","article-title":"The thrombotic events in polycythemia vera patients may be related to increased oxidative stress","volume":"23","author":"Durmus","year":"2014","journal-title":"Med. Princ. Pract."},{"key":"ref_42","first-page":"2860","article-title":"Increased oxidative stress in patients with essential thrombocythemia","volume":"17","author":"Durmus","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.37358\/RC.19.10.7581","article-title":"Crosstalk between Oxidative Stress, Chronic Inflammation and Disease Progression in Essential Thrombocythemia","volume":"70","author":"Gaman","year":"2019","journal-title":"Rev. Chim."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis","volume":"87","author":"Skov","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","article-title":"Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis","volume":"40","author":"Skov","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wong, W.J., Baltay, M., Getz, A., Fuhrman, K., Aster, J.C., Hasserjian, R.P., and Pozdnyakova, O. (2019). Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216810"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41375-020-0827-8","article-title":"The Nlrp3 inflammasome as a \u201crising star\u201d in studies of normal and malignant hematopoiesis","volume":"34","author":"Ratajczak","year":"2020","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Longhitano, L., Li Volti, G., Giallongo, C., Spampinato, M., Barbagallo, I., Di Rosa, M., Romano, A., Avola, R., Tibullo, D., and Palumbo, G.A. (2020). The Role of Inflammation and Inflammasome in Myeloproliferative Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082334"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The Inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fphar.2015.00262","article-title":"NLRP3 inflammasome and its inhibitors: A review","volume":"6","author":"Shao","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/jcp.29268","article-title":"Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases","volume":"235","author":"Lu","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The Inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"E7766","DOI":"10.1073\/pnas.1702946114","article-title":"NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy","volume":"114","author":"Nakanishi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1073\/pnas.0611496104","article-title":"Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling","volume":"104","author":"Duncan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: Mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/jmv.26217","article-title":"Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease","volume":"93","author":"Lucchesi","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","article-title":"Differential requirement for the activation of the inflammasome for processing and release of IL-1\u03b2 in monocytes and macrophages","volume":"113","author":"Netea","year":"2009","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"109595","DOI":"10.1016\/j.biopha.2019.109595","article-title":"Pyroptosis: A new frontier in cancer","volume":"121","author":"Fang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41422-020-0295-8","article-title":"Toward targeting inflammasomes: Insights into their regulation and activation","volume":"30","author":"Christgen","year":"2020","journal-title":"Cell Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41467-018-03669-z","article-title":"The E3 ubiquitin ligase Pellino2 mediates priming of the NLRP3 inflammasome","volume":"9","author":"Humphries","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e44766","DOI":"10.15252\/embr.201744766","article-title":"USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation","volume":"19","author":"Worboys","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1084\/jem.20160933","article-title":"NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain","volume":"214","author":"Stutz","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1172\/JCI83669","article-title":"NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22","volume":"126","author":"Spalinger","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ni1459","article-title":"A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses","volume":"8","author":"Mayor","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kelley, N., Jeltema, D., Duan, Y., and He, Y. (2019). The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133328"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41467-020-15497-1","article-title":"Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fimmu.2019.00085","article-title":"Cell type specific roles of nf-kb linking inflamation and thrombosis","volume":"10","author":"Mussbacher","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.humimm.2020.09.001","article-title":"Genetic polymorphisms and expression of NLRP3 inflammasome-related genes are associated with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"81","author":"Zhou","year":"2020","journal-title":"Hum. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.immuni.2012.02.014","article-title":"Structures of the HIN Domain: DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 Receptor","volume":"36","author":"Jin","year":"2012","journal-title":"Immunity"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1007\/s12010-014-0819-0","article-title":"Self-oligomerization of ASC PYD domain prevents the assembly of inflammasome in vitro","volume":"172","author":"Narayanan","year":"2014","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Liew, E.L., Araki, M., Hironaka, Y., Mori, S., Tan, T.Z., Morishita, S., Edahiro, Y., Ohsaka, A., and Komatsu, N. (2016). Identification of AIM2 as a downstream target of JAK2V617F. Exp. Hematol. Oncol., 5.","DOI":"10.1186\/s40164-016-0032-7"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10875-013-9881-6","article-title":"AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation","volume":"33","author":"Zhang","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/CIRCULATIONAHA.117.033098","article-title":"Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability","volume":"138","author":"Paulin","year":"2018","journal-title":"Circulation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40035-016-0054-4","article-title":"The dual roles of cytokines in Alzheimer\u2019s disease: Update on interleukins, TNF-\u03b1, TGF-\u03b2 and IFN-\u03b3","volume":"5","author":"Zheng","year":"2016","journal-title":"Transl. Neurodegener."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.molimm.2014.10.008","article-title":"Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis","volume":"63","author":"Peelen","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molcel.2014.03.029","article-title":"Inflammasomes and metabolic disorders: Old genes in modern diseases","volume":"54","author":"Robbins","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_83","first-page":"4063562","article-title":"NLRP3 Inflammasome and Inflammatory Diseases","volume":"2020","author":"Wang","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2018.22.1.1","article-title":"Role of inflammasomes in inflammatory autoimmune rheumatic diseases","volume":"22","author":"Yi","year":"2018","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"ref_86","unstructured":"Galimberti, C.S., Barat\u00e8, F., Ricci, S., Balducci, G., Governato, G., Fulvio, E., Elefante, F., Ferro, A., Di Paolo, L., and Baglietto, M.P. (2020, January 11\u201321). Clinical and biological features distinguish myeloid diseases from myeloid disorders associated with autoimmune diseases [e-poster presentation, EP1076]. Proceedings of the 25th European Hematology Association Annual Congress (Virtual)."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcmd.2014.12.005","article-title":"Activation of non-canonical TGF-\u03b21 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis","volume":"54","author":"Ciaffoni","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.4049\/jimmunol.1003998","article-title":"IL-1\u03b2 and TGF-\u03b2 Act Antagonistically in Induction and Differentially in Propagation of Human Proinflammatory Precursor CD4 + T Cells","volume":"187","author":"Hebel","year":"2011","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0950-3536(11)80013-2","article-title":"Transforming growth factor \u03b2 and interleukin-1: A paradigm for opposing regulation of haemopoiesis","volume":"5","author":"Ruscetti","year":"1992","journal-title":"Baillieres. Clin. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000479103","article-title":"Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome","volume":"138","author":"Piatek","year":"2017","journal-title":"Acta Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ejh.13198","article-title":"Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group","volume":"102","author":"Birgegard","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.exphem.2015.11.002","article-title":"Activation of the NLRP3 inflammasome by cellular labile iron","volume":"44","author":"Nakamura","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1073\/pnas.1620458114","article-title":"Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia","volume":"114","author":"Gupta","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1172\/JCI124804","article-title":"Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome\/interleukin 1\u03b2-driven venous thrombosis","volume":"129","author":"Yadav","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross Talk Pathways between Coagulation and Inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"49","DOI":"10.11613\/BM.2012.006","article-title":"Inflammation and hemostasis","volume":"22","author":"Margetic","year":"2012","journal-title":"Biochem. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tcb.2014.12.009","article-title":"Mechanisms of inflammasome activation: Recent advances and novel insights","volume":"25","author":"Vanaja","year":"2015","journal-title":"Trends Cell Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"18143","DOI":"10.1074\/jbc.M109.004804","article-title":"The pannexin 1 channel activates the inflammasome in neurons and astrocytes","volume":"284","author":"Silverman","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and Regulation of NLRP3 Inflammasome Activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbrc.2016.12.161","article-title":"The NLRP3 inflammasome and bruton\u2019s tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation","volume":"483","author":"Murthy","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5702103","DOI":"10.1155\/2018\/5702103","article-title":"NLRP3: A novel mediator in cardiovascular disease","volume":"2018","author":"Zhou","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/jth.14246","article-title":"Tissue factor at the crossroad of coagulation and cell signaling","volume":"16","author":"Zelaya","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/B978-0-12-801430-1.00003-2","article-title":"Activation of the NLRP3 inflammasome by proteins that signal for Necroptosis","volume":"545","author":"Kang","year":"2014","journal-title":"Methods Enzymol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/ATVBAHA.117.309315","article-title":"Tissue Factor Prothrombotic Activity Is Regulated by Integrin-arf6 Trafficking","volume":"37","author":"Rothmeier","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1172\/JCI94495","article-title":"Caspase-11-mediated endothelial pyroptosis underlies endotoxemia-induced lung injury","volume":"127","author":"Cheng","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1182\/blood-2013-05-504449","article-title":"Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation","volume":"122","author":"Hottz","year":"2013","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaci.2017.01.017","article-title":"Human NACHT, LRR, and PYD domain\u2013containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase","volume":"140","author":"Liu","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1074\/jbc.M113.505636","article-title":"Localization and functionality of the inflammasome in neutrophils","volume":"289","author":"Bakele","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1172\/JCI87532","article-title":"Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury","volume":"127","author":"Leaf","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"33416","DOI":"10.18632\/oncotarget.26058","article-title":"Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy","volume":"9","author":"Singer","year":"2018","journal-title":"Oncotarget"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/561\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:08:26Z","timestamp":1760159306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":112,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22020561"],"URL":"https:\/\/doi.org\/10.3390\/ijms22020561","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}